The article states 'better efficacy, safety and patient compliance than other treatments.?"
I agree on compliance ...but did Arikace Phase2 FEV score beat the Phase3 podhaler FEV reduction? ...just wondering.
YES ARIKACE DOES.......
Cystic Fibrosis Patients with Pseudomonas Lung Infections
About 70% of patients with cystic fibrosis develop a chronic lung infection due to Pseudomonas aeruginosa. This infection causes a mucous build up that leads to inflammation and lung deterioration. In fact, patients lose from 1% to 3% of their lung function each year of infection. Since there is no existing cure, life expectancy is very short, with the average patient living 37 years. There is an urgent need for a treatment with better efficacy, safety and durability.
Currently, Novartis (NVS) markets an inhaled tobramycin, termed TOBI, for psuedomonas lung infections in cystic fibrosis. However, Novartis' TOBI has shown significant disadvantages when compared to Arikace. Novartis's therapy takes up to 3 hours per day and requires two or three sessions of dosing. Arikace is the first ever once daily treatment for this indication and leads to an increased patient compliance. Furthermore, the dosing schedule is 28 days on and 56 days off, which is a significant advantage over current therapies.
In Phase III trials, TOBI also showed that lung function declined to baseline or lower at the end of 24 weeks of treatment. In Insmed's Phase II trials, Arikace showed statistically significant improvement in function throughout the 28-day treatment period, and that improvement was sustained through the off-treatment period. Furthermore, resistance to TOBI by the bacteria has increased by 85% since 1999, so a new treatment is in dire need.
Since you brought it up, why don't you research and report back to the board. After all, if YOU agree on compliance, why don't you let us know about the others. If you don't do research, but rather spew an uninformed opinion, never mind.